Delic Holdings announces a new health & wellness therapy offered through its Ketamine Wellness Centers mental health clinics.
Delic Holdings announces a new health & wellness therapy offered through its Ketamine Wellness Centers mental health clinics.
Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.
Wesana reports its Q4 2021 financial results and announces closing of a financing.
Optimi Health announces receiving amendment to Health Canada's Dealer's License that will allow expand cultivation and research use of psilocybin and psilocin.
Awakn Life Sciences reports fourth quarter and full-year results for its fiscal year ending January 31, 2022. Annual revenues of CAD$236,037.
Incannex Healthcare announces a "shareholder loyalty option" to raise A$23.6 million (US$16.5 million). For every two shares purchased, investors will receive a "piggyback option".
Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.
Field Trip announces its corporate decision to separate Field Trip Health and Field Trip Discovery into separate companies.
Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Private psychedelics company, Terran Biosciences announces a drug development partnership with Sanofi S.A. for the development and commercialization of two late-stage CNS drugs.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now